A substantial body of evidence shows that broad improvements to end-of-life care are within reach. In Dying in America, a consensus report from the Institute of Medicine (IOM), a committee of experts finds that improving the quality and availability of…
Category: IOM
Review of NASA’s Evidence Reports on Human Health Risks: 2014 Letter Report
NASA’s Human Research Program developed a collection of evidence reports that provide “the current record of the state of knowledge from research and operations” for more than 30 human health and performance risks related to long-duration and exploration spaceflights. To review NASA’s evidence reports, the IOM assembled a multi-disciplinary committee with expertise in aerospace medicine, occupational health, radiation medicine, human performance, systems engineering, human-computer interaction, internal medicine, physiology and cardiovascular health, immunology, behavioral health and sociology, task simulation and training, and biomedical informatics.
Vital Signs: Core Metrics for Health and Health Care Progress
With support from the Blue Shield of California Foundation, the California Healthcare Foundation, and the Robert Wood Johnson Foundation, the Institute of Medicine (IOM) convened a committee to identify core measures for health and health care. In VITAL SIGNS: Core Metrics for Health and Health Care Progress, the committee proposes a streamlined set of 15 standardized measures, with recommendations for their application at every level and across sectors. Ultimately, the committee concludes that this streamlined set of measures could provide consistent benchmarks for health progress across the nation and improve system performance in the highest-priority areas.
Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings – Summary of a Joint Workshop
Stem cells offer tremendous promise for advancing health and medicine. Whether being used to replace damaged cells and organs or supporting the body’s intrinsic repair mechanisms, stem cells hold potential to treat such debilitating conditions as Parkinson’s disease, diabetes, and spinal cord injury. Though clinical trials of stem cell treatments are underway around the world, the evidence base to support the medical use of stem cells remains limited. Therapies offered at clinics around the world generally have not received stringent regulatory oversight and have not been tested with rigorous trials. The IOM, the National Academy of Sciences, and the International Society for Stem Cell Research held a workshop to examine the global pattern of treatments and products being offered, the range of patient experiences, and options to maximize the well-being of patients, either by protecting them from dangerous or ineffective treatments or by steering them towards effective treatments.